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Abstract
Background Sarcopenia, the loss of muscle strength and mass, predicts adverse outcomes and becomes common with age.
There is recognition that sarcopenia may occur at younger ages in those with long-term conditions (LTCs) as well as those with
multimorbidity (the presence of two or more LTCs), but their relationships have been little explored. Our aims were to describe
the prevalence of sarcopenia in UK Biobank, a large sample of men and women aged 40–70 years, and to explore relationships
with different categories of LTCs and multimorbidity.
Methods We used data from 499 046 participants in the baseline of UK Biobank. Our main outcome was probable
sarcopenia based on maximum grip strength below sex-specific cut-points. Participants’ LTCs were recorded during an inter-
view and categorized against a hierarchy. We used logistic regression to examine the independent associations between each
category of LTCs and probable sarcopenia, including adjustment for age, sex, and body mass index. We also examined the as-
sociation with multimorbidity.
Results Probable sarcopenia had an overall prevalence of 5.3% and increased with age. The categories with the strongest
associations with probable sarcopenia were musculoskeletal/trauma [OR 2.17 (95% CI: 2.11, 2.23)], endocrine/diabetes [OR
1.49 (95% CI: 1.45, 1.55)], and neurological/psychiatric [OR 1.39 (95% CI: 1.34, 1.43)] LTCs. Almost half of the sample
(44.5%) had multimorbidity, and they were at nearly twice the odds of probable sarcopenia [OR 1.96 (95% CI: 1.91, 2.02)] com-
pared with those without.
Conclusions We have shown an overall prevalence of 5.3% of probable sarcopenia at ages 40–70 in UK Biobank. The risk of
probable sarcopenia was higher in those with some categories of LTCs, suggesting that these groups may stand to benefit from
assessment of sarcopenia, during mid-life as well as old age.
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Introduction
Sarcopenia, the accelerated loss of muscle strength and mass,
is important as it predicts a range of adverse outcomes1,2 and
it is amenable to interventions including resistance exercise
training and nutritional supplementation.3 The recent
European Working Group on Sarcopenia in Older People 2
(EWGSOP2) consensus definition enables the clinical identifi-
cation of sarcopenia in several respects.4 Firstly, it recom-
mends cut-points for low muscle strength and mass.
Secondly, it introduces the concept of probable sarcopenia:
the presence of low strength based on poor performance in
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grip strength or chair rise tests, as a basis on which to begin in-
tervention when assessment of muscle mass is not available.
Finally, it highlights that sarcopenia is primarily an age-related
condition but is also thought to occur at younger ages second-
ary to the presence of long-term conditions.
The links with long-term conditions mean that sarcopenia
is of growing interest to a wide range of clinical specialties.5
Studies highlight an increased prevalence of sarcopenia in
those with chronic obstructive pulmonary disease,6 chronic
heart failure,7 and chronic liver disease.8 Interactions with
skeletal muscle may also be important in the pathogenesis
of long-term conditions, for example, osteoporosis9 and heart
failure.10 Long-term conditions also do not typically occur in
isolation. Multimorbidity, commonly defined as the presence
of two or more long-term conditions, is the norm among
users of health care and those aged 65 and above.11 It is as-
sociated with a range of adverse outcomes including all-cause
mortality, increased health care costs, reduced quality of life,
depression, and functional limitation.12–14 There has been
comparatively little research into the overall relationship be-
tween sarcopenia and multimorbidity. Previous work includes
the finding that the number of long-term conditions present
in an individual is inversely related to their grip strength15–
18 and muscle mass.19 More recently, it has been recognized
that some categories of long-term conditions are more
strongly associated with impairments in physical function
than others.20 An understanding of which categories of
long-term conditions pose the greatest risk of sarcopenia
would be helpful as it could focus the assessment of
sarcopenia to those most likely to benefit from interventions.
The aims of the present study were therefore (i) to de-
scribe the prevalence of sarcopenia in a large sample of
adults including those in middle age and (ii) to investigate
the relationships between probable sarcopenia and different
categories of long-term conditions, in terms of individual cat-
egories and multimorbidity (the number of categories
present).
Methods
UK Biobank is a large prospective epidemiological study de-
signed to investigate the roles of genetic, lifestyle, and envi-
ronmental factors in health and disease in mid-life to later
life.21 In summary, 502 536 participants aged 37–73 were re-
cruited and seen for baseline assessment at 22 centres in
England, Wales, and Scotland between 2006 and 2010. Ethi-
cal approval for UK Biobank was obtained from the North
West Multi-Centre Research Ethics Committee.
Assessment of probable and confirmed sarcopenia
Grip strength was measured at baseline in UK Biobank by a
trained research nurse using a Jamar handheld dynamometer.
Onemeasurement was taken from both hands with the partic-
ipant in the seated position with their forearms on armrests.
We used the maximum of the available values.22 We used
the cut-points for weak grip strength (indicating probable
sarcopenia) as recommended in the EWGSOP2 definition of
<27 kg inmen and<16 kg in women.4,23We considered those
unable to perform grip strength measurement in either hand
due to health reasons (arthritis, previous stroke, or other
health problems, meaning that they were unable to perform
the test) as having weak grip strength for the purpose of
analyses.
Appendicular fat-free mass was measured using
bioimpedance analysis with a Tanita BC-418MA body compo-
sition analyser.24 Those with a pacemaker, those unable to
stand, those unwilling to remove their shoes, or women
who reported that there was any possibility they might be
pregnant were excluded. We used data from UK Biobank par-
ticipants (n = 4350) who underwent a dual-energy x-ray ab-
sorptiometry in a later assessment to produce an equation
to estimate appendicular lean mass (ALM) from the appen-
dicular fat-free mass values: ALM (kg) = (0.958 × [Appendicular
fat-free mass (kg)])  (0.166 × G)  0.308, with G taking
value 0 if female and 1 if male. For full details, please see
the Supplementary Methods section in the supporting
information.
Standing height was measured using a Seca 202 height
measure, and we expressed ALM relative to height squared.
We used the cut-points as recommended in the EWGSOP2
definition of <7 kg/m2 in men and 6 kg/m2 in women.4
We considered all participants with weak grip strength to
have at least probable sarcopenia, including those who had
not completed ALM measurement. We considered those with
weak grip strength and low ALM to have confirmed
sarcopenia. UK Biobank did not include measurement of
physical performance although participants were asked to de-
scribe their own walking pace as unable to walk, slow, steady
average, or brisk. We therefore considered participants with
confirmed sarcopenia and who reported that they were un-
able to walk or walked at a slow pace to have low physical
performance25 to have severe sarcopenia.
Assessment of long-term conditions,
multimorbidity, and other characteristics
Participants were asked if they had ever been told by a doctor
that they had one or more of the following illnesses: heart at-
tack, angina, stroke, high blood pressure, blood clot in leg,
blood clot in lung, emphysema/chronic bronchitis, asthma,
or diabetes. Those who reported any of those conditions, or
of having a history of cancer or any other serious illness or
disability, were then asked to complete an interview in which
a research nurse recorded details of all long-term conditions
against a hierarchical tree of over 450 conditions similar to
that used in the ICD-10 classification.26 We summarized the
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responses as binary variables for the presence or absence of
one or more conditions in each top-level category, with a sep-
arate variable for those reporting a history of one or more
cancer(s). We categorize the number of categories each par-
ticipant had into none, one, two, and three or more, with the
latter two considered to represent multimorbidity.
Weight was measured at the same time as the
bioimpedance measurement. We expressed body mass index
(BMI) (weight/height2) both as a continuous variable and
using standard cut-points. Participants were asked if they
had falls in the last year, classified as none, one, or two or
more.
Statistical analyses
We excluded the small number of participants aged under 40
or over 70 and those with missing data for grip strength,
height, weight, or long-term conditions (see Supporting Infor-
mation, Figure S1). For the main analyses, we classified par-
ticipants into either no sarcopenia (normal grip strength) or
probable sarcopenia (weak grip strength). We produced de-
scriptive statistics for each group and used logistic regression
to explore the associations between each category of long-
term condition and probable sarcopenia, including adjust-
ment for age, sex, BMI category, and other categories of
long-term conditions.
In further analyses, we produced descriptive statistics for
those in the main analyses with probable sarcopenia and
measurement of ALM, divided into those with ALM-for-
height above and below the EWGSOP2 cut-points. We per-
formed all analyses using Stata version 14.0.27
Results
The prevalence and characteristics of participants
with probable sarcopenia
A total of 499 046 participants had information available on
grip strength, BMI, and the presence of long-term conditions
(for more details, see Supporting Information, Figure S1).
Probable sarcopenia had an overall prevalence of 5.3% and
was associated with fall(s) in the last year and reporting being
unable to walk or walking at a slow pace as shown in Table 1.
Probable sarcopenia became more common with age: 2.5%,
4.5%, and 7.6% in the 40–49, 50–59, and 60–70 age groups,
respectively.
The relationship between probable sarcopenia,
long-term conditions, and multimorbidity
Those with probable sarcopenia were more likely to have
each category of long-term conditions, as shown in Table 1.
For example, 50.1% of those with probable sarcopenia had
one or more cardiovascular conditions compared with
35.9% of those without (P < 0.001). Most categories of
long-term conditions continued to have associations with
probable sarcopenia, following adjustment for the other cat-
egories, BMI, and gender as shown in Figure 1. The strongest
independent associations were seen for
musculoskeletal/trauma conditions [OR 2.17 (95% CI: 2.11,
2.23)], endocrine/diabetes [OR 1.49 (95% CI: 1.45, 1.55)],
neurological/psychiatric [OR 1.39 (95% CI: 1.34, 1.43)], eye
conditions [OR 1.33 (95% CI: 1.26, 1.4)], and cardiovascular
conditions [OR 1.29 (95% CI: 1.26, 1.33)].
Almost half of the sample (44.5%) had multimorbidity
(two or more categories of long-term conditions). This was
more common in those with probable sarcopenia (64.8%)
than those without (43.4%). The increase in the prevalence
of probable sarcopenia with both age and number of cate-
gories of long-term conditions is shown in Figure 2. Those
with multimorbidity had almost twice the odds of probable
sarcopenia compared with those without [OR 1.96 (95% CI:
1.91, 2.02)], after adjustment for age, sex, and BMI
category.
The prevalence and characteristics of participants
with confirmed sarcopenia
Of those with probable sarcopenia, 770 (2.9%) did not have
measurement of ALM. Compared with those with probable
sarcopenia who had ALM measurement, this group was
more likely to be male, to have weaker grip strength, to
be obese, to have three or more systems affected by
long-term conditions, to report two or more falls in the last
year, and to report walking at a slow pace (see Supporting
Information, Table S1). Among the 25 091 participants with
probable sarcopenia and who had a measurement of ALM,
1670 (6.4%) had confirmed sarcopenia (low ALM-for-
height), a prevalence of 0.3% among the entire sample.
The characteristics of participants with confirmed
sarcopenia are shown in Supporting Information, Table S2.
When compared with those with weak grip and normal
ALM-for-height, many of their characteristics were similar.
However, a key difference seen was in BMI, such that under-
weight was much more common, with a mean (standard de-
viation) BMI: 19.6 (2.0) kg/m2 among those with confirmed
sarcopenia compared with 28.3 (5.3) kg/m2 among those
without. Of those with confirmed sarcopenia, 404 (24.5%)
reported being unable to walk or walking at a slow pace,
and we therefore considered them to have severe
sarcopenia. This was in fact a smaller proportion than that
seen in the weak grip and normal ALM-for-height group:
27.6% (P < 0.001).
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Discussion
Summary of findings
We found an overall prevalence of probable sarcopenia of
5.3% among UK Biobank participants aged 40–70 years at
the time of assessment. We saw independent associations
of probable sarcopenia with most categories of long-term
conditions, particularly the musculoskeletal/trauma,
endocrine/diabetes, neurological/psychiatric, eye, and
cardiovascular categories. The prevalence of probable
sarcopenia increased with both age and the number of cat-
egories of long-term conditions, as illustrated by the finding
of a similar prevalence in those aged 40–49 with three or
more categories of long-term conditions to those aged
60–70 with only one. Participants with multimorbidity
(two or more categories of long-term conditions) were at
almost twice the odds of having probable sarcopenia com-
pared with those without. Finally, we saw a low prevalence
of confirmed sarcopenia of 0.3%. The main difference
Table 1 Characteristics of sample by probable sarcopenia status
Characteristic [N = 499 046 and all values n (%) unless shown]
No sarcopenia
n = 472 375 (94.7%)
Probable sarcopenia
n = 26 671 (5.3%)
Age [mean (SD)] 56.3 (8.1) 59.9 (7.2)
Age category
40–49 114 083 (24.2) 2948 (11.1)
50–59 158 618 (33.6) 7422 (27.8)
60–70 199 674 (42.3) 16 301 (61.1)
Female gender 255 332 (54.1) 16 407 (61.5)
Maximum grip (kg) [mean (SD)]
Women 25.9 (5.6) 11.8 (3)
Men 42.6 (8.1) 22.1 (4.3)
BMI (kg/m2) [mean (SD)] 27.4 (4.8) 28.1 (5.4)
BMI category
<18.5 2341 (0.5) 280 (1)
18.5 ≤ BMI < 25 154 638 (32.7) 7667 (28.7)
25 ≤ BMI < 30 201 391 (42.6) 10 582 (39.7)
BMI ≥ 30 114 005 (24.1) 8142 (30.5)
Conditions(s) by category
Cardiovascular 169 664 (35.9) 13 370 (50.1)
Respiratory/ENT 82 992 (17.6) 6122 (23)
Gastrointestinal 73 916 (15.6) 6119 (22.9)
Renal/urology 21 651 (4.6) 1711 (6.4)
Endocrine/diabetes 48 457 (10.3) 4985 (18.7)
Neuro/psych. 64 888 (13.7) 5351 (20.1)
Musculoskeletal/trauma 97 979 (20.7) 11 139 (41.8)
Haematology/dermatology 25 635 (5.4) 1918 (7.2)
Gynaecology/breast 25 271 (5.3) 1824 (6.8)
Immunological/systemic 39 970 (8.5) 2564 (9.6)
Infections 8767 (1.9) 654 (2.5)
Eye 17 110 (3.6) 1833 (6.9)
History of cancer 38 594 (8.2) 2905 (10.9)
Number of categories affected
0 117 311 (24.8) 3077 (11.5)
1 150 077 (31.8) 6307 (23.6)
2 108 853 (23) 6824 (25.6)
3+ 96 134 (20.4) 10 463 (39.2)
ALM/height2 (kg/m2) [mean (SD)] (n = 491 551)
Women 7.1 (0.8) 7.2 (1)
Men 8.8 (1.1) 8.7 (1.3)
Falls in last year (n = 496 880)
0 381 162 (81) 17 639 (67.1)
1 61 103 (13) 4415 (16.8)
2+ 28 321 (6) 4240 (16.1)
Self-reported walk speed (n = 496 845)
Unable to walk 1166 (0.2) 401 (1.5)
Slow pace 33 261 (7.1) 6966 (26.5)
Steady average pace 248 064 (52.7) 13 550 (51.6)
Brisk pace 188 070 (40) 5367 (20.4)
ALM, appendicular lean mass; BMI, body mass index; ENT, ear nose and throat; SD, standard deviation.
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between those with confirmed sarcopenia and those with
weak grip and normal muscle mass was that those with
confirmed sarcopenia had lower average BMI.
Comparison with existing studies
The concept of probable sarcopenia is a recent one, and we
are not aware of other studies that have assessed its preva-
lence in community settings. We are also not aware of stud-
ies that have examined the prevalence of sarcopenia at
younger ages, with a recent systematic review reporting a
minimum age of 55 years across 109 prevalence studies.28 Fi-
nally, we are not aware of studies that have specifically exam-
ined associations between long-term conditions and
sarcopenia, although two closely related areas of investiga-
tion are the associations of multimorbidity with grip strength
as a continuous variable and with other measures of physical
function, as described in the succeeding texts.
Several studies have shown inverse relationships between
hand grip strength and the total number of long-term condi-
tions in older individuals.15–18,29 The present analyses are
consistent with this evidence, in which we have shown this
relationship using the EWGSOP2 cut-points for weak grip
strength. However, a striking finding is that the association
is also present in younger adults. Our analyses have
highlighted considerable heterogeneity in the relationship be-
tween long-term conditions and weak grip strength, with
some categories of long-term conditions having stronger in-
dependent associations with probable sarcopenia than
others. This is in keeping with findings from the development
and validation of a weighted index for the relationship be-
tween different long-term conditions and self-reported phys-
ical function,20,30 which included long-term conditions in the
same top five categories as we found for probable
sarcopenia, along with respiratory disease and a history of
non-skin cancer. Two of these categories, cardiovascular
and neuropsychiatric conditions, have also been found to
predict declines in walking speed and activities of daily
living.31
The recent definition of probable sarcopenia is intended to
allow recognition and management of sarcopenia in a clinical
setting, where it is acknowledged that measurement of mus-
Figure 1 Independent associations between probable sarcopenia and
each category of chronic conditions. Findings from logistic regression
model showing independent associations between having one or more
chronic conditions in each category and probable sarcopenia. Other var-
iables in model (not shown): age (as linear term), sex, and body mass in-
dex category. N = 499 046. ENT, ear nose and throat.
Figure 2 Prevalence of probable sarcopenia by age and number of categories of conditions. The prevalence of probable sarcopenia is shown for each
combination of age group and number of categories of chronic conditions. Men and women combined, N = 499 046.
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cle mass may not be possible.32 Indeed, a proportion of the
current sample did not undergo bioimpedance analysis, and
this group appeared to be in worse health than those who
did. In clinical practice, it may therefore be relevant to note
when this test is not completed as it may identify a group
at risk of worse outcomes. Among those with probable
sarcopenia who completed bioimpedance analysis, the main
difference we observed between those with confirmed
sarcopenia and those with weak grip but normal ALM-for-
height was that the former group had lower BMI. We previ-
ously noted this in a study of 85 year olds.33
Interpretation of findings
Probable sarcopenia is an example of impaired physical func-
tion that is thought to have complex relationships with individ-
ual long-term conditions and multimorbidity, including
bidirectional effects.34 The associations we have demon-
strated may be due to confounding, for example, by lifestyle
risk factors such as lower physical activity. However, there
are also several possibilities by which the associations may
be causal. Firstly, other studies highlight that adult grip
strength and some long-term conditions have common ge-
netic factors.35,36 Secondly, arthritis such as at the wrist joint
may lead to reduced grip strength. Thirdly, it is likely that some
long-term conditions have deleterious effects on skeletal mus-
cle tissue. For example, patients with diabetes have been
shown to have higher levels of collagens surrounding muscle
fibres37 that may impair force transmission and also lead to re-
duced expression of mitochondrial genes.38 Alternatively,
medications used to manage some long-term conditions, such
as oral steroids, may cause loss of muscle mass as a side effect.
An improved understanding of the biological mechanisms un-
derlying these possibilities is needed if we are to prevent and
treat probable sarcopenia in the setting of multimorbidity.
Methodological considerations
Whilst UK Biobank is recognized to have a degree of healthy
responder bias39 and hence, the prevalence estimates in this
study are likely to be lower than the values in the general
population, the large sample size and mid-life focus of UK
Biobank allowed us to investigate the independent associa-
tions of each category of long-term conditions, including at
younger ages than in previous sarcopenia studies. UK Biobank
did not include the chair stand test, proposed by EWGSOP2 as
an alternative to grip strength for identifying probable
sarcopenia, and it also did not include tests such as walking
speed to allow us to identify those with severe sarcopenia (al-
though we were able to use reported walking speed as a
proxy).
In order to make the findings generalizable in other set-
tings, we used categories of long-term conditions as our ex-
posures, although an alternative would have been to
examine associations with individual conditions. Finally, an
area for future work would be to explore if particular clusters
of categories have stronger associations with sarcopenia than
suggested by their individual associations.40
Conclusions
We have shown an overall prevalence of probable
sarcopenia at ages 40–70 in UK Biobank of 5.3%, with the
risk increasing with age. We have also shown that probable
sarcopenia is associated with specific categories of long-
term conditions as well as multimorbidity at ages 40 and
above. The strength of association between different cate-
gories of long-term conditions and probable sarcopenia var-
ied, with musculoskeletal/trauma, endocrine/diabetes,
neurological/psychiatric, eye, and cardiovascular conditions
appearing to confer the greatest risk. These findings are im-
portant as they suggest that particular groups could be
targeted for interventions in mid-life aimed at the preven-
tion and treatment of sarcopenia.
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